Received: 2 April 2019
Accepted: 23 July 2019
First Online: 8 August 2019
Change Date: 6 November 2019
Change Type: Correction
Change Details: Following publication of the original article , the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells”.
Ethics approval and consent to participate
: Approval for this retrospective study was obtained from the University of Miami IRB.
: Individual patient consent was not applicable as no information in this article are identifiable.
: MU, JCC, JSB are employees of Agenus. BAW is receiving research funding from Agenus. Remaining authors declare no competing interests.